Because of this diversified model — cell‑line licensing, antibody discovery, small‑molecule R&D — VIVALIS presents itself not just as a service provider but as a biotech innovator. This hybrid model can offer stability (through licensing revenue) while allowing high‑risk/high‑reward innovation (through drug discovery). The company remains listed on Euronext Paris (ticker VLS), and is considered part of biotech indices in Europe. Vivalis review